1. Home
  2. BLZE vs EDIT Comparison

BLZE vs EDIT Comparison

Compare BLZE & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Backblaze Inc.

BLZE

Backblaze Inc.

HOLD

Current Price

$3.63

Market Cap

222.5M

Sector

Technology

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.32

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLZE
EDIT
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
222.5M
206.0M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
BLZE
EDIT
Price
$3.63
$2.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$7.60
$4.92
AVG Volume (30 Days)
949.5K
1.6M
Earning Date
05-06-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
58.56
37.50
EPS
N/A
N/A
Revenue
$145,835,000.00
$31,937,000.00
Revenue This Year
$10.28
N/A
Revenue Next Year
$11.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.27
132.64
52 Week Low
$3.54
$0.91
52 Week High
$10.86
$4.54

Technical Indicators

Market Signals
Indicator
BLZE
EDIT
Relative Strength Index (RSI) 36.62 53.26
Support Level $3.61 $1.84
Resistance Level $5.04 $2.36
Average True Range (ATR) 0.15 0.18
MACD 0.01 0.00
Stochastic Oscillator 21.84 52.91

Price Performance

Historical Comparison
BLZE
EDIT

About BLZE Backblaze Inc.

Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: